Article Versions Notes

Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova GK, Kandolf L, Chiarion-Sileni V, Mohr P, Karanikolova TS, Teterycz P, et al. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers. 2024; 16(21):3558. https://doi.org/10.3390/cancers16213558

Weichenthal, Michael, Joanna Mangana, Iva Gavrilova, Iwona Lugowska, Gergana Krumova Shalamanova, Lidija Kandolf, Vanna Chiarion-Sileni, Peter Mohr, Teodora Sotirova Karanikolova, Pawel Teterycz, and et al. 2024. "Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe" Cancers 16, no. 21: 3558. https://doi.org/10.3390/cancers16213558

Weichenthal, M., Mangana, J., Gavrilova, I., Lugowska, I., Shalamanova, G. K., Kandolf, L., Chiarion-Sileni, V., Mohr, P., Karanikolova, T. S., Teterycz, P., Espinosa, E., Schnecko, P., Cheng, P., Bender, M., Jiang, S., Burke, T., Ascierto, P. A., Gogas, H., Rodas, I. M., ... for the EUMelaReg Consortium. (2024). Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers, 16(21), 3558. https://doi.org/10.3390/cancers16213558